Inverting the clinical trial/physician relationship: The future (and data) is in the practice

Traditionally, in the pharmaceutical and biotech worlds, a pharma company finds a candidate product and works with a group of doctors to test that product under careful standards and procedures. If the product shows therapeutic value and safety, it becomes available to prescribers to administer to patients for that purpose.

The roles of the commercial company and the doctor’s practice are well understood in this scenario, but they have always created tension. Product companies have the pressures of recouping their research investments, and doctors’ offices and hospitals are seen as inefficient for the purposes of conducting clinical trials. The resulting stereotypes aren’t necessarily fair, but fairness isn’t always top-of-mind when incentives are slightly different.

To fix this tension, there have been a number of efforts to encourage and enable healthcare providers to think and act more like pharma when it comes to clinical trials. These efforts have included supplementing staff at healthcare practices and providing or integrating systems to make things more “clinical trial friendly”. I’m growing to believe, and trends are beginning to show, that we’ve had this whole thing backwards.

Look at what is really happening and some of the big breakthroughs in the past years. Some of the larger healthcare groups, running some of the largest hospitals in the US, see an astonishing number of patients annually. These patient visits number in the millions. Skilled doctors see patterns in data, illness, and diseases and are using this vantage point to drive research. Practicing physicians involved in research are in the best position to select and perfect the therapies that will work, based on their access to patients and their growing experience.

Wiser research organizations, the National Cancer Institute (NCI), pharmaceutical companies, and even technology providers see this and the ones leading the curve are changing longstanding paradigms. From the vantage point of the healthcare provider, research is one part of what they do. It’s interwoven with a busy schedule of patient visits, procedures, and a complex financial responsibility for billing and business management, made even more difficult by the changing healthcare payer landscape.

All the while, physicians and medical practitioners continue to hold the keys to unlocking the toughest healthcare problems of our time. They have access to patients and the expertise that comes from seeing and managing health issues day after day.

So, what to do? Here are three suggestions.

First, look at the doctors’ systems in use as the center of their universe. Electronic health records systems (eHR) are the primary collection tools for doctors to gather patient information. Rather than trying to replace them or shove another system in front of office staff, figure out how to work within the eHR without major functional changes.

Second, invest in the relationship. Pharma, technology providers, and research service companies have spent millions on proprietary systems to support processes that aren’t very sensitive to the issues in healthcare practice. Reevaluating even some of that investment and redirecting it could pay major dividends in overcoming the inefficiencies that have been major complaints in the clinical trial process. There are transparency and compensation rules about how this is done, but they are in place to keep people honest, not to stifle research. The returns on these investments will reap dividends.

Finally, get creative and more invested in translational medicine. There is tremendous value in the intellectual property being generated in healthcare practices, provider networks, and researchers. The NIH published their “Roadmap for Medical Research” in 2008. In 2011, a group of research leaders authored an article (“Crossing the Chasm: Information Technology to Biomedical Informatics“) providing a status update and details on the effort. This initiative needs to be more inclusive, with buy-in and support from the entire group of interested parties, industry and technology providers included. All parties could benefit from a solid business model and investment in this area. The returns would be extraordinary.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

Johnson & Johnson (NYSE:JNJ) this week pledged $10 million this week to fight racism and injustice in the U.S. In a response to the deaths of George Floyd in Minneapolis, Breonna Taylor in Louisville, Ky., and Ahmaud Arbery near Brunswick, Ga., J&J CEO Alex Gorsky said the $10 million pledge will span the next three years. It will… […]

B. Braun announced today that Caroll H. Neubauer will retire at the end of August after 24 years leading the Melsungen, Germany–based medical and drug delivery device giant’s North America operations. Jean-Claude Dubacher, a former Johnson & Johnson and Abbott executive who already took over Neubauer’s role as CEO of B. Braun Medical at the… […]

The FDA warned laboratories today that using certain transport media for COVID-19 samples with Hologic (NSDQ:HOLX) Panther and Panther Fusion diagnostic systems can produce deadly cyanide gas. Transport media is the liquid that maintains a specimen sample while it is transported to a laboratory. The Hologic Panther systems and others that have been sterilized using bleach can… […]

Sahajanand Medical Technology (SMT) announced today that its Hydra TAVR device has received the CE Mark for the treatment of severe aortic stenosis. The Hydra aortic valve is a self-expandable, nitinol-based, supra annular aortic system with a mechanism for recapturing the valve during deployment, according to Mumbai, India-based SMT. This property helps in precise placement of… […]

German researchers have developed mats made of biodegradable fibers only a few microns thick that could prove advantageous to deliver certain drugs to the brain. The drug nimodipine, for example, could prevent nerve cells from dying after brain surgery. Health providers already use it to treat cerebral hemorrhages, but it degrades very quickly and has… […]

Packaging Compliance Labs, LLC (PCL) will be expanding its current operations in Kentwood, Mich. In addition to a capital investment of $2.57 million, the company will bring 27 new jobs to the area. The medical device and pharmaceutical packaging engineering and validation firm, along with its sister company, SmartStart Medical (SSM), will take on the… […]

The number of heart attack patients seeking urgent hospital care has dropped by more than 50% worldwide during the COVID-19 outbreak, according to a survey by the European Society of Cardiology (ESC). The survey of 3,101 healthcare professionals in 141 countries was conducted in mid-April.The findings are published in European Heart Journal — Quality of… […]

Resolution Medical recently announced that it has brought on industry veteran David Blaeser as its new CEO. The Fridley, Minn.–based medical device contract manufacturing and development company noted that Blaeser has 35 years of experience leading teams at Boston Scientific, Velocimed, Nidus, Endometabolic Solutions, Libra Medical, and Zift Medical. Most recently, he was founder and CEO… […]

Major medtech companies with a presence in the Minnesota have been calling for peace, unity and racial justice following the death of George Floyd in police custody and the resulting demonstrations and violence. Executives from Boston Scientific, Medtronic and the Medical Alley Association have penned open letters expressing their concerns and pledging to do better.… […]

Summit Medical recently announced that it has delivered more than 1 million FDA-compliant face shields for to protect healthcare workers and returning business employees during the COVID-19 pandemic. St. Paul-based Summit Medical said it designed, engineered and manufactured the face shields in just 8 weeks, cross-training staff to assemble them and saving 65 employees’ jobs.… […]

Pavmed (NSDQ:PAVM) today announced it plans to develop and use Canon Virginia’s commercial-grade and scalable aqueous silk fibroin molding process to manufacture its DisappEAR molded pediatric ear tubes. Under terms outlined in a letter of intent, PAVmed and Canon Virginia propose to enter into two sequential agreements covering a 5-phase project culminating in the commercialization of… […]

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Market Summary > Current Price

The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Medtech news in a minute?
We Deliver!
MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.